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Abstract:  
 
Diabetes is the seventh leading cause of death in the U.S. and is currently 
estimated to affect 25.8 million people.  Type 2 diabetes or adult-onset diabetes is 
prevalent due to the rise in obesity.   Pre-diabetes (fasting blood glucose between 100-
125 mg/dl) is a condition with an elevated blood glucose that is not high enough to be 
categorized as diabetes. Dietary intervention in individuals with moderately elevated 
blood glucose may help delay the development of diabetes.  The consumption of fruits 
and vegetables has been investigated for their effect on chronic diseases like diabetes.  
This study investigated the effects of supplementation of freeze-dried mango on clinical 
parameters of individuals with moderately elevated blood glucose.  The mango fruit is 
rich in vitamins and minerals as well as the phenolic compounds quercetin and 
mangiferin that possess anti-inflammatory and antioxidant properties.  In a crossover 
design, individuals with fasting blood glucose between 100-125 mg/dl were recruited and 
asked to consume either a freeze-dried mango (10 g) or a placebo daily for 12 weeks with 
3-4 weeks wash-out period between treatments. After 12 weeks of supplementation, there 
were no significant differences in glycemic indices between mango and placebo groups.  
There were also no significant differences in body composition or clinical parameters in 
either group with time or treatment.   Unlike our earlier findings, chronic consumption of 
the mango fruit has a modest effect in lowering blood glucose but does not cause 
hyperglycemia in individuals with moderately elevated blood glucose. 
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CHAPTER I 
 
 
INTRODUCTION 
  
 
  The Center for Disease Control (CDC) reported that in the last 20 years there has been 
an increase in obesity in the United States, affecting all regions in the country and individuals of 
all ages 1. They reported that over one-third of U.S. adults and 17% of children and adolescents 
are obese 1. The CDC defines obesity as a range of weight that is greater than what is considered 
healthy for a given height or a body mass index (BMI) > 30 kg/m2 1. As obesity increases, other 
health-issues such as type 2 diabetes (T2D) also increase. Diabetes is preceded by pre-diabetes, a 
condition where blood glucose levels are higher than normal (i.e., fasting blood glucose 100 to 
125mg/dL), but not high enough to be considered for diabetes (fasting blood glucose ≥ 125 
mg/dL) 2. Of those diagnosed as pre-diabetic, 15% to 30% will develop T2D within the next five 
years if lifestyle changes are not implemented to improve their condition 1.   
To explain the pathophysiology of diabetes, a basic understanding of carbohydrate 
metabolism and the role that insulin plays is important to discuss.  Under normal conditions, 
postprandial glucose signals the release of insulin from the beta cells of the pancreas to normalize 
blood glucose. The hormone, insulin, binds to a cell membrane receptor and induces a 
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signaling cascade that leads to the translocation of the glucose transporter to the cell membrane of 
insulin-sensitive tissues such as skeletal muscle and adipose tissue. This glucose transporter 
facilitates the entry of glucose into the cell, which then leads to normalization of blood glucose 
levels. Three actions happen in T2D: peripheral resistance to insulin, altered production of insulin 
in pancreatic beta cells, or an increased production of hepatic glucose. These alterations can 
stimulate the progression of each other leading to the development of T2D 3. Alterations in 
insulin production contributing to the disease can be seen with changes in incretin hormones such 
as gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1). Along with insulin’s 
primary effects on glucose homeostasis, it also plays a role in many other cellular events such as 
lipid metabolism, glycogen synthesis, gene transcription, protein synthesis and degradation and 
DNA synthesis 4. 
Obesity, sedentary lifestyle and dietary habits play a role in the development of T2D. 
Weight loss is one of the important lifestyle modifications for those with elevated blood glucose.  
Excess adipose tissue can hinder glucose uptake and contribute to insulin resistance that results to 
high blood glucose levels. This occurs in part because adipose tissue secretes inflammatory 
cytokines such as tumor necrosis factor alpha (TNF-α) which impairs insulin signaling. Exercise 
has been shown to promote glucose uptake, alleviating the hyperglycemic burden on many 
diabetic patients. Richter and colleagues assessed plasma insulin levels after exercise sessions and 
found that a single exercise session can increase skeletal muscle’s response to insulin 5.  
Therefore, both exercise and weight loss are important in the prevention and management of 
T2D.  In addition to exercise, calorie restriction can contribute to weight loss. It is recommended 
that a moderate calorie restriction of 250-500 calories per day can delay or prevent the 
development of T2D 6.   
In addition to lifestyle changes, pharmacological options are also available for managing 
blood glucose. Commonly used diabetes medications act through three general mechanisms of 
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action; 1) increase insulin secretion like sulfonylureas and meglitinides, 2) improve insulin action 
like metformin and thiazoledinediones (TZDs), and 3) reduce glucose absorption by preventing 
the break-down of carbohydrates like alpha glucosidase inhibitors. Metformin is the most 
commonly used medication for T2D and acts by reducing fasting hepatic glucose output and 
improving peripheral insulin resistance 7. Pharmacological options for diabetes are effective in 
modulating blood glucose; however, it is associated with unwanted side effects ranging from 
gastrointestinal effects and weight gain to renal and cardiovascular risks 7. Therefore, alternative 
approaches for the management of T2D are needed.   
A diet containing a variety of fruits and vegetables has been reported to reduce the risk of 
many chronic diseases including T2D 8. Fruits and vegetables contain bioactive compounds that 
can help delay the development of many chronic conditions. For example, a clinical study 
demonstrated that supplementation of whole blueberry powder for six weeks improved insulin 
sensitivity in obese, non-diabetic, and insulin-resistant individuals 9. One variety of lettuce, 
Rutgers Scarlet lettuce, has anti-diabetic properties because of its ability to stabilize glucose 
levels and increase insulin sensitivity 10. A meta-analysis found that greater consumption of 
blueberries, grapes, apples, bananas, and grapefruit are associated with reduced risk of T2D 8. 
The positive effects of these fruit and vegetables on improving aspects of T2D are mostly 
attributed to the different polyphenols and antioxidants. 
One fruit that is rich in bioactive components such as vitamin C, beta-carotene, 
phosphorus, and potassium, as well as fiber and phenolic compounds that have been shown to 
have health benefits is the mango fruit. The phenolic compounds quercetin and mangiferin found 
in mango have been shown to positively affect blood glucose concentrations 11. Quercetin was 
shown to increase the number of pancreatic islet cells, increase insulin release and reduce plasma 
glucose in streptozocin (STZ)-induced diabetic rats 12. Duang and colleagues speculated that the 
glucose-lowering effect of mangiferin is by hindering glucose absorption from the intestine 13.  
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Muruganandan and colleagues also suggested that mangiferin decreases glucose absorption from 
the intestine 14. This assumption is supported by the findings of Yoshikawa and colleagues that 
reported mangiferin inhibits α-glucosidase enzymes involved in the digestion of carbohydrates 14, 
15.  The bioactive compounds in mango are shown to decrease oxidative stress 13, 16, 17. Increased 
oxidative stress through the production of reactive oxygen species (ROS) is often observed in 
diabetes 18. These reactive species can alter the structure or function of cellular proteins, lipids, 
and nucleic acids and can also trigger the activation of stress signaling pathways like the 
serine/threonine kinase cascade which can lead to insulin resistance 18.  
Most of the studies on the health effects of mango have been on the phenolic compounds 
(mangiferin and quercetin) extracted from the different parts of the mango plant or flesh of the 
mango fruit. Limited studies have investigated the health effects of the pulp of the mango fruit.  A 
study by Lucas and colleagues investigated the effects of freeze-dried mango pulp on adiposity, 
glucose metabolism, and lipid profiles in mice fed a high fat diet 19. The effects of mango were 
also compared to the hypolipodemic drug (i.e. fenofibrate) and hypoglycemic drug (i.e. 
rosiglitazone). The investigators reported that mango was comparable to fenofibrate and 
rosiglitazone in preventing increases in fat mass and percent body fat and also decreased insulin 
resistance, improving insulin sensitivity 19. Guevarra et al. compared the glycemic response of 
mango to that of other tropical fruits (chico, pineapple, and papaya) in T2D individuals 11. Chico 
and mango induced a lower blood glucose response compared to pineapple and papaya, and this 
was attributed to the fiber and other nutrients found in these fruits contributing to the delay in 
their rate of digestion and absorption 11. These findings give validity to the idea that mango is an 
acceptable fruit for diabetic patients to consume because it does not cause a rapid increase in 
blood sugar. More research needs to be done to investigate the effects of whole mango fruit on 
clinical parameters of individuals with elevated blood glucose. Moreover, research investigating 
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the appropriate dose of mango supplementation administered to individuals with elevated blood 
glucose is needed. 
This study investigated the effects of chronic mango consumption in modulating blood 
glucose levels in individuals with elevated blood glucose. Based on previous animal and limited 
human studies, we hypothesize that freeze-dried mango and its bioactive components will 
improve blood glucose concentrations in individuals with moderately elevated blood glucose. The 
specific aims of the study are to investigate the effects of daily supplementation of freeze-dried 
mango (10g/d) for 3 months on 
1. parameters of glucose homeostasis 
2. anthropometrics, and  
3. inflammatory markers and antioxidant status of individuals with moderately elevated 
blood glucose. 
The aims were achieved using a cross-over study design of twenty five individuals with 
moderately elevated blood glucose. They were asked to consume 10 g/d of freeze-dried mango or 
placebo for 3 months with a 3-4 weeks washout period in between treatments. Blood glucose, 
body composition, inflammatory markers and antioxidant status were assessed at baseline and at 
the end of treatment period. 
 Some of the limitations of our study include: (1) we cannot be certain that the supplement 
was consumed daily; (2) the dose of mango (10g/d) was a relatively small amount compared to 
some previous studies 14, 60, 68; (3) a 3 month intervention period might not be enough time for the 
supplementation to cause significant changes; and (4) a home testing glucometer was used for 
screening the participants instead of glycosylated hemoglobin (HgbA1C) values.  
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
Prevalence of obesity, pre-diabetes, and diabetes 
Obesity is a health concern in the US and worldwide as its prevalence increases every 
year.  In the United States, there was a dramatic increase in obesity in the twenty year span 
between 1990 and 2010. In 2010, there were twelve states that recorded their obesity prevalence 
to be greater than 30% compared to no states having an obesity prevalence of 30% or more ten 
years earlier 1. More than 35.7% of US adults and approximately 17% of children and adolescents 
were obese in 2010. Health conditions related to obesity include heart disease, stroke, certain 
cancers, and type II diabetes (T2D). It is estimated that the medical cost of obesity in the US in 
2008 was $147 billion. As the incidence of obesity grows so do the medical costs associated with 
it 1. It is estimated that medical costs for obese people were $1,429 higher per year compared to 
those of normal weight. 
The obesity epidemic has resulted in an increase in the prevalence of pre-diabetes and 
T2D.  Weight gain has been found to be one of the most important risk factors in the development 
of T2D 20.  In 2012, there were a total of 29.1 million people in the US with diabetes 1. The 
estimated total cost of diabetes in the US as of 2012 was $245 billion 1. Therefore, intervention 
strategies are needed to reduce the incidence and cost associated with T2D. 
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Obesity and diabetes 
Adipose tissue is a normal part of the human body and acts as an energy reservoir. The 
body stores any excess energy in adipose tissue to be used during periods of lower energy intake.  
Adipocytes can expand by increasing either in size (hypertrophy) or number (hyperplasia) of fat 
cells. Other functions of the adipose tissue include: 1) protecting organs from mechanical 
damage, 2) secreting a variety of bioactive peptides and adipokines, which can act by autocrine, 
paracrine, and endocrine mechanism, and 3) their involvement in many biological processes 
including neuroendocrine and immune function 21, 22. Although adipose tissue performs important 
functions in the body, excess amounts can have detrimental health effects. Excess adipose tissue 
or obesity is associated with insulin resistance, hyperglycemia, dyslipidemia, hypertension, and 
pro-thrombotic pro-inflammatory states 22.  
Adipose tissue secretes adipokines that have endocrine functions. Leptin, tumor necrosis 
factor alpha (TNF-α), interleukin-6 (IL-6), plasminogen activator inhibitor-1 (PAI-1), resistin, 
visfatin and adiponectin are proteins secreted from adipose tissue that add to the complex 
relationship of obesity, insulin resistance, and inflammation. Leptin plays a role in regulating 
appetite and metabolism 23. The amount of leptin secreted is proportional to the adipose tissue 
mass. Under normal conditions, leptin regulates body weight and food intake, but in an obese 
individual, there seems to be resistance or insensitivity to leptin 24.  
Contradicting its role in cachexia, TNF-α was the first adipose derived factor shown to 
link obesity, inflammation, and diabetes 22, 24. TNF-α, manly produced by macrophages, has been 
found to increase in obesity and is positively related to insulin resistance 22. It is reported that in 
adipose tissue, TNF-α indirectly represses the genes associated with the uptake and storage of 
non-esterified fatty acids and glucose 22. The mechanism by which TNF-α contributes to insulin 
resistance is by hindering the uptake of glucose in peripheral tissues. Kinase activity involved in 
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the initial steps in insulin signaling is inhibited by TNF-α 25. TNF-α not only acts in adipose 
tissue, but also in the liver by reducing glucose uptake and metabolism and impairs insulin 
signaling 22.  
IL-6 is another cytokine secreted from the adipose tissue and is positively correlated to 
obesity, impaired glucose tolerance, and insulin resistance 22. As much as, one third of circulating 
IL-6 comes from the adipose tissue 22. IL-6 decreases insulin signaling by down-regulating 
expression of insulin receptor signaling components and suppressor of cytokine production 22. 
Therefore, elevated IL-6 concentration is implicated in obesity and insulin resistance and is a 
predictor for the development of T2D as well as CVD 22.   
Adiponectin, unlike leptin, TNF-α, and IL-6, has a strong inverse association with insulin 
resistance and the inflammatory state. Serum adiponectin levels are low when there is insulin 
resistance from obesity or lipodystrophy, and administration of adiponectin improves metabolic 
parameters in obesity or lipodystrophy 22, 26. Adiponectin concentrations are higher with weight 
reduction and improved insulin sensitivity 22. In the liver, adiponectin increases insulin sensitivity 
by regulating fatty acid metabolism through increasing fatty acid oxidation, and decreasing 
circulating non-esterified fatty acids 22. Adiponectin also suppresses hepatic glucose output aiding 
insulin sensitivity 22. In the muscle, adiponectin stimulates glucose and fatty acid oxidation 
suggesting anti-diabetic effects of adiponectin 22.  
In addition to adipokines, adipocytes also play a role in insulin resistance and 
development of T2D by secreting non-esterified fatty acids and glycerol. Chronically elevated 
circulating free fatty acids and glycerol induce insulin resistance in skeletal muscle by inhibiting 
glucose transport activity 27. This results in increased lipid oxidation and decreased glucose 
uptake contributing to insulin resistance 27. The inhibition of glycogen synthase activity may be a 
contributor in the decrease mobilization of glycogen 27. 
9 
 
Pre-diabetes and diabetes 
 Blood glucose levels are tightly regulated in healthy individuals, but as an individual 
advances toward T2D, defects in glucose homeostasis develop and over many years these small 
changes can lead to the development of T2D. This metabolic condition is characterized by 
disordered fuel homeostasis with hyperglycemia and altered lipid metabolism due to pancreatic 
islet β-cells not being able to secrete sufficient insulin to appropriately respond to the body’s 
needs during over-nutrition, inactivity, obesity, and insulin resistance 28. Under normal conditions 
when blood glucose levels are maintained, tissues like the liver, skeletal muscle, and heart are 
given optimal conditions to function properly. However, when blood glucose levels are not 
controlled and there is a chronic surplus, tissue and cell such as the pancreatic islet cells become 
overworked and over time become damaged. In addition to the pancreas, other tissues are also 
affected such as the adipose tissue, liver, skeletal muscle, and heart 28. 
 Pre-diabetics are individuals that have impaired fasting blood glucose (100 to 125 mg/dL) 
or impaired glucose tolerance and are at an increased risk of T2D 20. Pre-diabetes is the early 
stage of T2D and experiences impaired glucose tolerance but no symptoms are observed.  
Impaired glucose tolerance is characterized by increased insulin resistance in skeletal muscle and 
liver as well as altered β-cell function 20. As glucose concentration increases, the demand for 
insulin exhausts the β-cell resulting in impaired function. The combination of insulin resistance 
and impaired β-cell function is responsible for the increased risk of T2D in pre-diabetics 20. 
 In addition to impaired β-cell function, increased hepatic gluconeogenesis and 
glycogenolysis add to the surplus of glucose in circulation, which aggravates hyperglycemia.  
Impaired insulin secretion further allows for more glucose in circulation because insulin is not 
present to assist entry of glucose into tissues. When the body becomes resistant to insulin, tissues 
are incapable of using insulin to effectively transport and metabolize glucose, which causes the 
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pancreas to compensate by increasing production of insulin which can then lead to 
hyperinsulinemia and further contribute to the development of T2D 29. 
 The earliest sign of T2D is elevation of postprandial glucose, while also experiencing 
progressive insulin resistance. Under normal conditions, the body compensates with islet cell 
hypertrophy in order to increase insulin production to normalize circulating glucose, but in the 
progression of T2D, insulin production is insufficient to maintain euglycemia. This disrupted 
process further contributes to a high glucose load after a meal, which adds to the stress put on the 
beta cell to produce more insulin and contributes to the progression of this disorder 29.  An 
overload of fuel in the form of glucose is what drives the development of T2D 28.   
 Postprandial glucose is regulated by insulin secretion and suppression of hepatic 
gluconeogenesis and glycogenolysis. Insulin promotes glucose uptake into muscle and peripheral 
tissues to be used for energy or stored as glycogen. In T2D, glucose uptake by tissues is impaired 
and hepatic gluconeogenesis is not suppressed resulting in hyperglycemia. Under normal 
conditions, postprandial glucose stimulates insulin release from the beta cell. Insulin then binds to 
the cell surface receptor to allow glucose entry into the cell. Individuals with T2D have slightly 
diminished insulin receptor binding affinity and the cells do not respond to the presence of insulin 
and therefore do not allow the entry of glucose into the cell 29. The glucose transporter, GLUT4 is 
sensitive to insulin signaling and allows glucose entry into the cell. GLUT4 is found in high 
concentrations in skeletal muscle and adipose cells 29. In T2D, even though there is normal level 
of GLUT4, there is impaired glucose transport lending to the idea that there is abnormal insulin 
receptor binding or the translocation of GLUT4 to the cell surface is flawed 29. The defect in the 
signaling pathway between insulin receptor and GLUT4 translocation results in insulin resistance 
29. With down regulation of glucose transport system using GLUT4, there is an increase in plasma 
glucose concentration.  Increases of plasma glucose concentration of an extra 50-100 mg/dL 
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spanning for as little as 24 hours decreases GLUT4 translocation, significantly increasing insulin 
resistance 29.   
Insulin resistance is commonly the earliest indicator in the development of T2D 29.  A 
small amount of insulin resistance is normal for the body to use during times of short-term 
overfeeding.  During these times, skeletal and cardiac muscles develop insulin resistance to allow 
storage of excess nutrients in adipose tissue rather than having excess nutrients accumulate in 
other tissues contributing to steatosis and other metabolic stress 28. T2D is characterized by 
insulin resistance that results in hyperglycemia. Hyperglycemia contributes to beta cell 
deterioration and further exacerbates the disorder 29. As beta cells deteriorate, less insulin is able 
to be made and subsequently more hyperglycemia is expressed contributing to the vicious cycle.   
Not only is postprandial glucose elevated in T2D, but individuals also experience fasting 
hyperglycemia. This is due to an increase in hepatic glucose output via increases in 
glycogenolysis and gluconeogenesis, because insulin is not being used effectively and is unable to 
signal for the suppression of hepatic glucose output 29. The progression of the disease and lack of 
glycemic control is exacerbated by the ongoing deterioration of beta cell function adding to the 
decrease in insulin production 29. The glucose toxicity theory suggests that continual exposure of 
the pancreas to small increases in blood glucose over a long amount of time can have adverse 
effects on β-cells 30. 
Glucose toxicity of the pancreatic islet is defined as non-physiological and potentially 
irreversible β-cell damage caused by chronic exposure to supra-physiological glucose 
concentrations 30. High concentrations of glucose in the blood result in desensitization and 
exhaustion of the pancreatic β-cell due to chronic glucose stimulation 30. Another effect of high 
glucose concentration on the pancreas is β-cell exhaustion 30. Glucose toxicity is associated with 
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chronic oxidative stress which damages cellular components of insulin production resulting in 
decreased insulin secretion 30.  
Oxidative stress and diabetes 
Oxidative stress due to increase production of reactive oxygen species (ROS) is also 
implicated in T2D 30.  ROS are involved in many redox-regulatory mechanisms of cells to 
maintain a consistent redox-homeostasis, but can drastically increase due to certain factors such 
as mitochondrial stress, environment and diet. To balance the production and removal of ROS, 
antioxidant defenses are needed to scavenge the ROS 31.  In a reduced antioxidant status, ROS 
react with phospholipids of membranes causing membrane permeability and instability as well as 
inhibiting cell signaling contributing to problems such as insulin resistance 31. ROS can inactivate 
or degrade signaling proteins causing a disruption in insulin signal transduction resulting in 
insulin resistance 35. ROS may also activate nuclear factors leading to the production of other pro-
inflammatory cytokines, enhancing inflammation and generating other ROS. Obesity, a risk 
factor for T2D, is characterized by increased inflammation and cytokine production which 
aggravates oxidative stress 31.   
Hyperglycemia also plays a role in oxidative stress. High concentrations of glucose 
increase the mitochondrial proton gradient, which results in an over-production of electron donors 
by pathways like the tricarboxylic acid cycle (TCA) and electron transport chain 32. Chronic high 
glucose concentration increases production of mitochondrial superoxides that can damage tissues. 
One target of free radical reactions are unsaturated bonds in lipid membranes resulting in the loss 
of membrane fluidity and alignment. This damage culminates in inactivation, cross-linking, and 
denaturation of proteins 33. Majority of glucose uptake occurs in the skeletal muscle which 
activates the mitochondrial electron transport chain for energy production that can also lead to 
production of superoxides. Not all of the ROS can diffuse across the mitochondrial membrane 
13 
 
and therefore accumulate in the mitochondria causing degradation and damage to the organelle 35. 
Free radicals that are not neutralized by antioxidants can cause damage to DNA, lipids, proteins, 
and vital cellular structures 29. Pancreatic islet cells are especially vulnerable to ROS because they 
have a low level of antioxidants enzyme to neutralize the harmful ROS 32.   
Management of T2D 
 Lifestyle modification is recommended to decrease the risk of developing T2D. Weight 
loss through diet and exercise are encouraged as prevention methods because two of the main 
determinants in developing insulin resistance are obesity and lack of physical activity 36. 
Weight loss due to calorie restriction increases oxidative capacity of skeletal muscle, thus 
preventing lipid accumulation in the skeletal muscle and improving insulin sensitivity. Calorie 
restriction reduces free fatty acids (FFA), which is beneficial because an excess of FFA promotes 
the accumulation of  long-chain fatty acyl CoA, diacyglycerol and triglycerides that may promote 
the activity of protein kinase C and lead to insulin resistance 36. Therefore calorie restriction 
induced weight loss has positive effects by decreasing free fatty acid levels, which also contribute 
to improvements in insulin sensitivity 36.   
Exercise is another lifestyle factor that promotes insulin sensitivity. Exercise does not 
always result in weight loss but physical activity is still accompanied by improved insulin 
sensitivity in the absence of weight loss 36. The changes, though not accompanied by a reduction 
in body weight or a decrease in fat composition, are likely due to increased GLUT 4 content 36.  
Exercise that results in weight loss has a greater effect on insulin-stimulated glucose disposal 36.  
Improvements in insulin-stimulated glucose disposal due to exercise are usually short lived and 
diminish within a week of exercise cessation 36.   
Calorie reduction and exercise are lifestyle modifications for preventing T2D, but once 
T2D has developed, more aggressive treatment options such as pharmacologic options might be 
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necessary. There are three ways these pharmacological options help manage diabetes; increasing 
insulin secretion, improving insulin action, and reducing glucose absorption 7. The more 
commonly used medications to lower blood glucose include; sulfonylureas, biguanides, 
meglitinides, alpha-glucosidase inhibitors, and thiazolidinediones (TZDs) 37. Sulfonylureas and 
meglitinides stimulate pancreatic β-cells to release more insulin. Biguanides lower blood glucose 
by decreasing hepatic gluconeogenesis. Alpha-glucosidase inhibitors block the breakdown of 
starches in the intestine slowing the rise in blood glucose after a meal. TZDs assist insulin action 
in the muscle and fat while also reducing hepatic gluconeogenesis 37. 
Sulfonylureas and meglitinides are insulinotropic agents that are considered a first-line 
treatment for individuals that are not overweight (BMI< 25 kg/m2) 38. Sulfonylureas increase 
cytosolic free calcium, a second messenger that stimulates insulin release from the β-cell of the 
pancreas 39. These medications are taken before meals to stimulate the release of insulin for 
maintaining blood glucose. Since these treatment options stimulate the uptake of glucose it is 
possible it may cause hypoglycemia 37. Data on the actual incidence of hypoglycemia in 
individuals with T2D using either sulfonylureas or meglitindies is scarce, but the risk is still 
present 40.  
Metformin is a biguanide that is widely prescribed for T2D. It lowers blood glucose by 
decreasing fasting hepatic gluconeogenesis. Biguanides have been identified as a new class of 
complex I and adenosine triphosphate (ATP) synthase inhibitors 41. Metformin inhibits 
phosphorylation of targets of protein kinase A, which blocks glucagon-dependent glucose output 
from hepatocytes 42. Biguanides also make skeletal muscle more insulin sensitive by activating 
AMP-activated protein kinase (AMPK), which is important in insulin signaling and increases 
glucose uptake (ADA). Metformin is a first-choice treatment for overweight individuals (BMI> 
25 kg/m2) 38.  
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Alpha-glucosidase inhibitors are taken with meals and also a first-line treatment 
recommendation for overweight (BMI> 25 kg/m2) individuals 37. Alpha-glucosidase inhibitors 
interfere with the last step in carbohydrate digestion, conversion of disaccharides to 
monosaccharides in the gastrointestinal tract, which decreases absorption of glucose 43. 
TZDs are the most popular class of oral drugs used to improve insulin sensitivity. They 
accounts for up to 20 percent of the drugs prescribed to diabetics in the United States 44. An 
advantage of using TZDs is that they do not induce hypoglycemia as some comparable drugs like 
sulfonylureas 45. TZDs mimic or enhance certain actions of insulin on carbohydrate and lipid 
metabolism, which result in antihyperglycemic effects 46. TZDs increase fatty acid uptake and 
lipogenesis in adipose tissue 46. Though TZDs do not modulate insulin secretion in β-cells, it 
increases insulin sensitivity in hepatic and adipose tissue 47. TZDs stimulate transcriptional 
factors in adipose tissue by activating the nuclear receptor peroxisome proliferator-activated 
receptor gamma (PPARγ) 46. PPARs are ligand-regulated transcription factors that control gene 
expression by binding to the specific response elements in promoter region of DNA. When 
PPARs obligate as heterodimers with a retinoid X receptor (RXR), this interaction while still 
ligand dependent increases the rate of transcription of PPAR target genes involved in glucose and 
lipid metabolism 48. 
PPARs play a role as lipid sensors and regulators of lipid metabolism 48. Activation of 
PPARγ, by ligands such as TZDs dramatically improves peripheral insulin sensitivity and reduces 
plasma glucose concentrations 49. Though the exact mechanism is not fully understood, there are 
several possibilities as to how this drug improves peripheral insulin sensitivity and reduces 
plasma glucose concentrations. First, the benefits might be due to adipocyte differentiation where 
TZDs increase fat-cell number (hyperplasia), allowing for greater lipid storage capacity, which 
increases protection of non-adipose tissues such as muscle, liver, and pancreatic islets from 
excess lipid accumulation 49. Second, PPARγ agonists might act on mature adipocytes altering the 
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production of adipose-derived hormones or metabolic signals functioning to improve metabolic 
parameters in tissues and organs like muscle, liver, and pancreas 49.  
Rosiglitazone and pioglitazone are two drugs classified as TZDs. They are used in the 
treatment of T2D as monotherapy or combination therapy 50. In addition to decreasing blood 
glucose values, these drugs are also beneficial for cardiovascular parameters such as lipids, blood 
pressure, inflammatory biomarkers and endothelial function 50. However, there is evidence that 
these drugs can also contribute to edema, which can aggravate cardiovascular disease 50.  
Individuals with T2D are already at an increased risk for developing cardiovascular disease, 
which makes the use of TZDs, like rosiglitazone and pioglitazone, a challenge in the treatment of 
T2D. Though the use of TZDs like rosiglitazone and pioglitazone are effective in lowering blood 
glucose their side effects prove that other treatment options need to be explored.  
Fruit and vegetables and their glucose-lowering properties 
 Dietary strategies to alleviate metabolic complications of obesity are being investigated 
as complementary or even alternatives to pharmaceutical interventions 51. Fruits and vegetables 
have been found to possess many protective health benefits including lowering blood glucose and 
improving lipid profiles. 
 Whole blueberry powder added to a high-fat diet was found to inhibit early inflammatory 
events in adipose tissue protecting against obesity-associated insulin resistance 51. Improvement 
in intraperitoneal insulin tolerance test was also observed in the blueberry supplement group 
compared to the high fat control group. Additionally, the blueberry powder group showed 
increased skeletal muscle glucose uptake and decreased hepatic glucose production. These 
findings demonstrate that whole blueberry powder can improve glycaemia in obesity-induced 
insulin resistance 51.   
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 In addition to blueberries, raisins have been found to possess anti-hyperglycemic 
properties. Corinthian raisins are produced in Southern Greece and are high in fiber, complex 
carbohydrates, vitamins and minerals, and polyphenols, which have antioxidant properties and 
can influence intestinal glucose uptake 52. Healthy individuals or individuals diagnosed as having 
T2D given Corinthian raisins showed decreased glucose and insulin responses 52. Corinthian 
raisins exhibit a lower glycemic index and are an appropriate food for individuals with diabetes 
52.   
 Apples are the second most popular fruit consumed in the United States and also possess 
many health benefits including anti-hyperglycemic effect 53. High antioxidant and phenolic 
phytochemical compounds contribute to apples potential for reducing chronic diseases like T2D 
53.  Quercetin, a major component of the peel of an apple is a constituent associated with 
decreased risk for T2D 53. However, growing conditions, variety, and part of the fruit affects the 
kind and amount of bioactive compounds found in the fruit. A study by Barbosa and colleagues 
compared ten different apple varieties to measure their phenolic and antioxidant capacity 53. The 
peel of an apple has been reported to have a high antioxidant capacity, in fact, a whole apple 
(about 200g) can provide on average up to 40-50 mg total soluble phenolics, 25% of that from the 
peel 53. The studies previously discussed show that fruits, because of their antioxidant and 
phenolic components can have glucose-lowering capabilities.  
Studies on mango 
 Mango is another fruit with abundant antioxidant and phenolic components, which make 
it a potential natural product able to provide a protective role in modulating blood glucose and 
other clinical parameters 19. A study by Lucas and colleagues investigated the effects of freeze-
dried mango pulp on adiposity, glucose metabolism, and lipid profiles in mice fed a high fat diet.  
The effect of mango was also compared to the hypolipodemic drug (fenofibrate) and 
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hypoglycemic drug (rosiglitazone). This study found that mango was comparable to fenofibrate 
and rosiglitazone in preventing increases in fat mass and percent body fat and also lowered 
insulin resistance 19. Perpetuo and colleagues investigated the effects of three different doses of 
mango flour (5,10, and 15%) on normal and diabetic rats 54. They found that all three doses of 
mango significantly reduced glucose levels in diabetic rats with 30 days of treatment 54. They did 
a follow up study and found that 5% mango flour supplementation over 90 days significantly 
reduced glucose levels and increased hepatic glycogen in diabetic rats 54. 
Extract of the different parts of the mango plant have been investigated for their ability to 
lower blood glucose parameters. Muruganandan et al. used an animal model to investigate the 
effects of mango leaf extract rich in mangiferin in an animal model of type 1 diabetes, the 
streptozotocin (STZ)-induced diabetic rats 14. Mango leaf extract was shown to be as effective as 
insulin at lowering blood glucose, triglycerides, total cholesterol, LDL cholesterol, and increasing 
HDL cholesterol after 28 days of supplementation in STZ-induced diabetic rats 14. Aqueous 
mangiferin leaf extract was also decreased the progressive rise in glucose during a glucose 
tolerance challenge in STZ-induced diabetic rats 55. A study by Zhang and colleagues looked at 
the effects of mango leaf extract on glucose and triglyceride levels in mice. They found that 
mango leaves extract significantly reduced serum glucose and lipid concentrations 56. Protein and 
mRNA expression of GLUT4 was up-regulated in the group treated with mango leaves extract 
compared to the control group 56. Saleh and colleagues also investigated the effects of mango 
bark extract rich in mangiferin supplementation on STZ-induced diabetic rats. After 28 days, the 
mango bark extract decreased blood glucose, HOMA-IR, triglycerides, cholesterol, and TNF-α 
levels, while also increasing β-cell function and adiponectin levels 57. 
 The glucose lowering ability of mango has been compared to other fruits as well in 
clinical trials. A clinical study assessed postprandial glucose response of five fruits, banana, 
orange, pineapple, pawpaw, and mango, compared to a glucose solution in T2D subjects 58. The 
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results of this study showed that banana, orange, pineapple, mango and pawpaw had similar 
postprandial glucose values which were lower than those of a post-glucose load 58. The plasma 
glucose response of mango, pawpaw and orange were consistently lower, but not significantly, 
than banana and pineapple 58. The consistently favorable glycemic responses of mango make it a 
recommendable choice of fruit for diabetic individuals to consume 58. Another study showed that 
208.5 g mango lowered the postprandial glucose and insulin responses of ten diabetic female 
subjects when compared to their responses to banana, durian, pineapple and rambutan 59. Robels-
Sanchez and colleagues looked at the effects of mango in normolipidemic subjects 60. They 
divided the subjects into two groups, one consuming whole mango (including peel and seed) for 
30 days and the other consuming fresh-cut mango (excluding peel and seed) for 30 days. Both 
types of mango had significant effects on plasma antioxidant capacity and triacylglycerides 60.  
These findings indicate mango as a component of a healthy diet for hypertriacylglyceridemic 
prevention 60. Evans et al. found that after twelve weeks of supplementation mango significantly 
reduced fasting blood glucose in obese subjects and increased circulating insulin levels in male 
obese subjects 61. The animal and human studies discussed above demonstrates the hypoglycemic 
properties of mango, as well as its effects in improving common health complications associated 
with diabetes such as dyslipidemia.  
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CHAPTER III 
 
 
METHODOLOGY 
 
Study participants  
Male and female adults between 18-70 years of age with mild to moderate hyperglycemia 
(i.e. fasting blood glucose ≥ 100 ≤ 126 mg/dL) and currently not taking glucose-lowering 
medications with normal liver and kidney function test were recruited in the study. Individuals 
having any form of pre-existing disease (e.g., cancer, heart disease, etc.), or liver or renal 
disorders, who are pregnant or lactating, consuming mega-doses of antioxidants and/or fish oil 
supplements (>1g/day), abnormal hemoglobin concentrations (normal range: 12.0-18.0 g/dL), 
white blood cell count (normal range: 4.0-11.0 K/mm³), platelets (140-440 K/mm³), and liver 
enzymes (normal range for aspartate aminotransferase, AST: 7-40 units/L; alanine 
aminotransferase, ALT: 10-45 units/L), who smoke or use any form of tobacco, and consume 
more than 1 oz. of alcohol per day were excluded from this study.  
Study supplements 
 Mango and placebo supplements were prepared on the campus of Oklahoma State 
University. Ripe Tommy Atkins variety mango was purchased from a local market, freeze-dried,
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ground into a powder, and weighed into an opaque plastic bag (10g/bag). The dose of freeze-
dried mango powder (10g/d) and the variety were based on an animal study that found 1% mango 
to be effective at improving blood glucose and clinical parameters of mice fed a high fat diet and 
our recent human study 19, 61. The macronutrient composition of mango supplement used in the 
study is shown in Table 1. The placebo was prepared using yellow colored sugar, fiber (FiberStir 
LLC, Plymouth, MN) and powdered milk. The placebo supplement was adjusted to have similar 
carbohydrate, fat, protein and fiber content to that of the mango supplement and weighed into 
similar bags as the mango supplement.  
Table 1. Nutrient composition of the mango supplement 
Nutrients 
Amount per bag 
(10g freeze-dried mango) 
Carbohydrate (g) 8.58 
Protein (g) 0.501 
Fat (g) 0.175 
Fiber (g) 1.29 
Calcium (g) 7.92 
Phosphorus (mg) 12.3 
Calories (kcal) 37.9 
Nutrient composition was analyzed by NP Analytical (St. Louis, MO)
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Study design and visits 
 A cross-over study design was used. Participants were asked to consume the pre-
weighed, freeze-dried mango or placebo daily for 12 weeks with 3-4 weeks wash-out between 
treatments. No stipulations were given on how the supplement was to be consumed. Participants 
were also asked to maintain their normal diet, exercise, and lifestyle habits throughout the entire 
study. Study protocols were reviewed and approved by Institutional Review Board at Oklahoma 
State University (IRB Number HE.11.41).  
After an initial telephone pre-screening, participants came to the study site and fasting 
blood glucose was measured with a home glucometer testing kit (Onetouch, Shelton, CT). To 
qualify for the study fasting blood glucose should be between 100mg/dL and 125 mg/dL. If 
participants qualified, they were asked to come to the Stillwater Medical Center (Stillwater, OK) 
for a fasting blood draw. A summary of procedures for each visit is shown in Table 2. 
Table 2. Procedures performed during the study 
Procedures Visit 
1 
Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 
7 
Finger stick blood glucose 
measurement 
x       
Explain the study protocol and 
get consent  
x       
Medical history questionnaire x       
Anthropometric measurement x x x x x x x 
Blood pressure measurements x x x x x x x 
Physical activity questionnaire x  x x x x x 
3 day food record        
   Given x x x x x x  
   Collected  x x x x x x 
Fasting blood collection  x x x x x x 
Oral glucose tolerance test 
(OGTT) 
   x   x 
Urine pregnancy test (women 
participants of child-bearing age) 
 x  x x  x 
Body composition by dual 
energy xray absorptiometry 
(DXA) 
 x  x x  x 
Treatment assignment  x   x   
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Supplements        
   Given  x x  x x  
   Collected   x x  x x 
Calendar        
   Given  x x  x x  
   Collected   x x  x x 
Honorarium given  x x x x x x 
 
Questionnaires  
A medical history questionnaire was obtained from all study participants to ensure that all 
inclusion and exclusion criteria were met. A physical activity questionnaire was collected from all 
subjects at each visit to determine exercise habits and to make sure that they maintained these 
activities throughout the duration of the study. The physical activity questionnaire was based on 
the method of Anderson 62. This questionnaire breaks up daily physical activity into nine different 
categories: sleep, sedentary work, standing/walking, heavy physical work, biking or walking to 
work, leisure time, light activity, moderate activity, and strenuous activity. These categories 
describe the total amount of physical activity in an average week, which was reported in minutes 
per day or hours per week depending on the specific question. A 3-day food-record was collected 
at each visit to determine the participant’s dietary habits throughout the study. Nutrient intake 
was analyzed using the Diet Analysis Plus Software (Cengage, Farmington Hills, MI).   
Anthropometric measures and body composition 
 Height, weight, blood pressure, hip circumference, and waist circumference were 
measured at each visit. Height was measured using a Shorr Board stadiometer (Shorr Productions, 
Olney, MD), and weight using a digital wheelchair scale (Seca Southwest Scales, Amarillo, TX).  
After participants relaxed for a few minutes in a sitting position, blood pressure was measured 
twice using a digital blood pressure monitor (ReliOn, Oncue HealthCare Inc, Bennockburn, IL).  
Hip and waist circumference was measured using a standard measuring tape (Creative Health 
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Products, Ann Arbor, MI). The waist circumference was defined as the midpoint between the 
highest point of the iliac crest and the inferior portion of the costal margin in the mid-axillary 
plane. The hip circumference was determined at the level of the maximum posterior extension of 
the buttocks.   
Body composition measures were assessed at baseline and at the end of 3-months of each 
dietary supplementation using a dual-energy X-ray absorptiometry (DXA; Hologic, Bedford, 
MA). Subjects were scanned while lying in a supine position with arms at their sides. 
Measurements of body composition included percent fat mass, lean mass, and bone mineral 
content (BMC).  
Blood collection and oral glucose tolerance test (OGTT) 
  Fasting blood sample was drawn from the vein in the right or left arm by a licensed 
phlebotomist or a registered nurse at Stillwater Medical Center (Stillwater, OK) into a plasma or 
serum tube. Hepatic function, complete blood count, lipid profiles, glucose, glycated hemoglobin 
analyses were performed at Stillwater Medical Center. A portion of blood samples were taken to 
the Nutritional Sciences Department (Oklahoma State University, Stillwater OK), centrifuged at 
3200 x g for 20 minutes at 4ᴼ C to obtain serum and plasma, aliquoted, and stored at -80 ͦ C until 
further analyses.  
The OGTT was administered at the end of each dietary treatment at Stillwater Medical 
Center. After the baseline blood draw, participants were asked to drink a 75 g oral glucose 
solution within 5 minutes (Azer Scientific, Morgantown, PA). Blood samples were taken 2 hours 
after drinking the glucose solution and blood glucose was assessed at Stillwater Medical Center. 
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Plasma insulin, leptin, and adiponectin 
 Enzyme linked immunosorbent assay (ELISA) kits from EMD Millipore Corporation (St. 
Charles, MO) were used to determine plasma concentrations of insulin, adiponectin, and leptin. 
With ELISA, antigens from the sample react to the capture antibody on the surface of a 96-well 
plate. A specific detection antibody was added to the well and binds to antibody-antigen complex, 
which is then labeled with horseradish peroxidase followed by the substrate 3,3’,5,5’-
tetramethylbenzidine forming a colored solution. Absorbance was measured using a microplate 
reader (Biotek, Winooski, VT) and is directly proportional to the concentration of captured 
insulin, leptin, or adiponectin in the unknown plasma sample. 
 Serum thiobarbituric acid reactive substances (TBARS) and total antioxidant 
 Assay kits from Cayman Chemical Company (Ann Arbor, MI) were used to determine 
serum concentrations of TBARS and total antioxidants. Cellular oxidative stress results in the 
formation of reactive and unstable lipid hydroperoxides. The decomposition of these unstable 
peroxides derived from polyunsaturated fatty acids results in the formation of malondialdehydes 
(MDA), which can be quantified colorimetrically following its reaction with TBARS (Cayman 
Chemical Company, Ann Arbor, MI). This measurement is a well-established method for 
screening and monitoring lipid peroxidation. The assay of TBARS measures MDA reaction with 
TBA at high temperatures and data is collected colorimetrically at 530nm and 550nm.  
Total antioxidants activity is the sum of endogenous and food-derived antioxidants.  
Cooperation of all the antioxidants provides the greatest protection against reactive oxygen or 
nitrogen radicals rather than any single compound alone. Therefore, the overall antioxidant 
capacity can give more relevant biological information compared to the results of an individual 
component, because it considers the cumulative effect of all the antioxidants that are present 
(Cayman Chemical Company, Ann Arbor, MI). The assay for total antioxidant allows the 
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antioxidants in the sample to inhibit the oxidation of 2,2’-Azino-di-[3-ethylbenzthiazoline 
sulphonate] (ABTS) by metmyoglobin. The amount of ABTS produced was determined by 
reading the absorbance of 750 nm or 450 nm. Under the reaction conditions, the antioxidant in the 
sample will suppress the absorbance to a degree that is proportional to their concentration. 
(Cayman Chemical Company, Ann Arbor, MI). 
Cytokines and diabetes markers analysis using Bio-plex 
 Bioplex Pro cytokine and diabetes assay kits from Bio-Rad Laboratories (Hercules, CA) 
were used to measure twenty-seven different cytokines interleukin-1 beta (IL-1β), interleukin-1 
receptor antagonist (IL-1ra), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), 
interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 
(IL-10), interleukin-12 (IL-12), interleukin-13 (IL-13), interleukin-15 (IL-15), interleukin-17A 
(IL-17A), eotaxin, basic fibroblast growth factor (basic FGF), granulocyte colony-stimulating 
factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), interferon gamma 
(IFN-γ), interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 
(MCP-1), macrophage inflammatory protein 1alpha (MIP-1α), macrophage inflammatory protein 
1beta (MIP-1β), platelet-derived growth factor (PDGF), C-C motif chemokine 5 (CCL5) 
(RANTES), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF)) 
and ten different diabetes markers (connecting peptide (C-peptide), ghrelin, gastric inhibitory 
peptide (GIP), glucagon-like peptide-1 (GLP-1), glucagon, insulin, leptin, plasminogen activator 
inhibitor 1 (PAI-1),  resistin, visfatin).  
The Bio-Plex Pro assay quantifies multiple protein biomarkers in a single well of a 96-
well plate. This assay uses capture antibodies that are directed against the desired biomarkers and 
are covalently coupled to magnetic beads. The capture antibody attached to the magnetic beads 
reacts with the antigen in the sample. A biotinylated detection antibody was added to bind to the 
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antibody-antigen complex attached to the magnetic bead and then labeled with a final detection 
complex formed by the addition of streptavidin-phycoerythrin (SA-PE) conjugate. The 
phycoerythrin serves as a fluorescent indicator and the beads containing the complex were read in 
a Bio-Plex MAGPIX Multiplex Reader  and concentration was calculated based on a standard 
curve (Bio-Rad Laboratories, Inc. Hercules, CA). 
 Statistical analyses 
 All values are presented as mean ± standard deviation. Statistical data were computed and 
analyzed by one-way ANOVA using SAS software version 9.3 (SAS Institute, Cary, NC). The 
general linear model (GLM) procedure was used to calculate variance and least square means, 
while the means were compared using Fisher’s least significant difference. Data are considered 
significantly different with P value <0.05. 
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CHAPTER IV 
 
 
RESULTS 
 
Baseline characteristics  
The baseline characteristics of the participants are shown in Table 3. Twenty-eight 
individuals with slightly elevated blood glucose participated in the three month study. All 
screening blood glucose obtained using a home testing glucometer (Onetouch, Shelton, CT) was 
103.4 ± 3.7, and 106.9 ± 8.2 mg/dL for the mango and placebo treatments respectively. Twenty-
two individuals completed both arms of the study while six individuals finished only one arm of 
the study (four individuals only took the mango supplement while another two individuals took 
only the placebo). Therefore, twenty-six and twenty-four individuals received the mango and 
placebo supplement, respectively. The major reason for dropping out of the study and not 
crossing-over to the other treatment was time constraints, and one study participant had an 
allergic reaction to the mango supplement.  
The mean age of the subjects participants were 38.8 ± 14.1 and 44.0 ± 15.4 years for the 
mango and placebo groups, respectively (Table 3). The oldest study participant was seventy years 
old and the youngest was eighteen years old. Ten male and sixteen female participants took the 
mango supplement while seven male and seventeen female participants took the placebo 
supplement. There were no differences in weight, height, and BMI at baseline among the two 
groups. 
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Food intake and physical activity 
 There were no significant differences found in food intake of the subjects on either 
supplement before or after supplementation. The mean total caloric intake of the study 
participants for both groups during the entire study was around 1800 kcal (Table 4). Vitamin C 
intake tended (P=0.0615) to increase for the mango group after 12 weeks of supplementation 
(Table 4).  
There was no significant difference in the amount of sleep and physical activity between 
the two groups before and after supplementation. The study participants spend about 400 minutes 
of sleep per week (Table 5). They also spend about 170 minutes of moderate activity per week 
(Table 5). 
Anthropometrics, body composition, and lipids and hepatic panel 
 There were no significant differences between the two groups of baseline blood pressure, 
waist and hip circumference, and BMI. After 90 days of treatment there were no significant 
differences in weight, systolic blood pressure, diastolic blood pressure, BMI, and waist or hip 
circumference between the mango and the placebo groups (Table 6). There were also no 
significant differences in whole body area, bone mineral content (BMC), bone mineral density 
(BMD), fat mass, or percent body fat with mango supplementation when compared to the control 
(Table 6). Additionally, when these variables were examined for differences due to time, there 
were no differences between the two groups when comparing the change from baseline with 
theses parameters. 
 There was no significant difference between mango and placebo as well as change from 
baseline in lipid profile assessed by measuring total cholesterol, triglyceride, LDL, HDL, VLDL 
cholesterol, and LDL/HDL (Table 7). No significant differences were observed with treatment 
and time when measuring serum total protein, albumin, and globulin to monitor possible diabetic 
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nephropathy (Table 5). Hepatic function was assessed by measuring aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), and alkaline phosphatase and there were no differences 
with treatment and time in these parameters (Table 7). Bilirubin, which is associated with a lower 
prevalence of oxidative stress-mediated diseases like T2D, significantly increased (P=0.0017) for 
both treatment groups over the 90 day study (Table 7). 
Diabetes parameters, cytokines, and lipid peroxidation 
 There was no significant difference in fasting blood glucose, HbA1C%, insulin, HOMA-
IR or blood glucose after two hours of glucose tolerance test with mango supplementation 
compared to the control. There was also no difference between the two treatments when 
comparing change from baseline (Table 8). 
 Ghrelin, the hunger hormone, was significantly lower (P=0.0130) in the mango group 
compared to the control but there was no significant difference with change from baseline (Table 
9). There were no significant differences in C-peptide, GIP, GLP-1, and visfatin (an indicator of 
β-cell function). Glucagon, an antagonist of insulin was also found to not be significant with 
treatment and time. Four markers of obesity and weight control; leptin, adiponectin, PAI-1 and 
resistin were measured and there were no significant differences with mango supplementation 
compared to the control as well as no change with time (Table9). 
 IL-13 an anti-inflammatory protein was significantly lower (P=0.0284) in the mango 
group when compared to the control, but there was no difference in change from baseline. The 
pro-inflammatory protein, TNF-α, was significantly lower (P=0.0399) in the mango group when 
compared to the control, but similar to the IL-13 was not changed with time (Table 10). 
Antioxidants were measured to assess oxidative stress and were found to be significantly lower 
(P=0.0371) in the mango group when compared to the control group (Table 10). TBARS was also 
measured to assess lipid peroxidation and there were no significant differences. There was no 
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significant difference in pro-inflammatory cytokines, IL-1β, IL-8, IL-12p70, IFNγ, IP-10, MCP-
1, MIP-1α ,MIP-1β, or RANTES. Anti-inflammatory proteins, IL-1ra, IL-6 and IL-10 displayed 
no significant differences. Immunity was assessed by measuring IL-2, IL-4, IL-5, and IL-7, and 
there were no significant differences found. There were no significant differences when 
measuring IL-9, FGF, GCSF, PDGF-BB, and VEGF to assess cell growth (Table 10).  
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Table 3. Baseline characteristics  
Parameter 
Mango                      
(n=26) 
Placebo                                           
(n=24) 
P value  
No.  of male (female) participants 10 (16) 7 (17)  
Age (yrs) 38.8 ± 14.1 44.0 ± 15.4 0.3712 
Weight (lbs) 188.6± 32.8 196.5± 40.6 0.5810 
Height (in) 65.8 ± 3.4 66.0 ± 3.4 0.8804 
BMI (kg/m2) 30.8± 6.9 31.9± 6.2 0.6695 
Screening blood glucose (mg/dL) 103.4± 3.7 106.9± 8.2 0.1734 
Values are mean ± standard deviation. Significance level set at P value <0.05. Body mass index (BMI); screening blood glucose was assessed       
by a home-testing glucometer (Onetouch, Shelton, CT). 
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Table 4.  Effect of 90 day supplementation with mango or a placebo on dietary intake of individuals with moderately elevated blood glucose 
Parameter Mango  Placebo  P value P value 
 
Baseline   
(n=17) 
Final         
(n=20) 
Change§ 
Baseline     
(n=18) 
Final         
(n=18) 
Change§ Time 
Treat- 
ment 
Time X 
Treat- 
ment 
change 
from 
baseline 
Total Energy 
(kcal) 
1858.2± 
865.6 
1728.2± 
766.3 
130.0± 358.4 
1762.3± 
546.2 
1845.5± 
875.2 
-83.1± 
996.0 
0.9057 0.9568 0.5902 0.4406 
Macronutrients 
Protein (g) 75.3± 24.3 66.4± 19.0 9.0± 16.3 67.8± 20.5 74.3± 22.6 -6.5± 30.8 0.8276 0.9683 0.1673 0.0962 
Carbohydrate (g) 
224.4± 117.7 
219.0± 
94.3 
5.4± 51.5 228.1± 76.1 
245.6± 
151.7 
-17.5± 
167.4 
0.8357 0.6020 0.6940 0.6165 
Sugar (g) 92.5± 50.1 77.1± 42.3 15.4± 28.7 82.7± 41.0 80.2± 54.3 2.5± 47.9 0.4599 0.7828 0.5962 0.3766 
Fiber (g) 16.4± 8.7 15.9± 10.8 0.9± 5.1 18.4± 6.6 18.3± 15.2 0.1± 16.5 0.8664 0.4684 0.8853 0.8577 
Lipids 
Total Fat (g) 73.3± 38.3 65.1± 42.4 8.3± 23.6 66.0± 25.5 63.8± 33.2 2.3± 32.1 0.5581 0.6317 0.7401 0.5619 
Saturated Fat  (g) 24.2± 12.4 21.4± 13.1 2.8± 9.0 21.3± 9.3 20.8± 11.6 0.5± 10.4 0.5822 0.5604 0.6998 0.5188 
MUFAs (g) 19.4± 11.5 17.0± 11.7 2.5± 11.2 18.8± 9.6 16.9± 10.2 1.8± 12.6 0.4264 0.9089 0.9096 0.8851 
PUFAs (g) 11.8±12.2 11.6± 11.0 0.2± 9.2 10.6± 5.7 10.9± 10.5 -0.4± 12.9 0.9714 0.7220 0.9162 0.8945 
Trans fatty acid 
(g) 
0.4± 0.7 0.7± 0.8 -0.2± 0.8 0.5± 0.5 0.4± 0.4 0.1± 0.5 0.7449 0.6021 0.2630 0.1478 
Cholesterol (mg) 
215.1± 112.9 
211.5± 
114.6 
3.6± 145.1 195.6± 86.5 
237.0±178.
2 
-41.4± 
191.0 
0.5633 0.9260 0.4918 0.4680 
Omega 6 (g) 9.1± 11.1 9.6± 10.0 -0.6±8.2 8.3± 5.2 8.9 ± 10.0 -0.6± 12.0 0.8100 0.7527 0.9959 0.9948 
Omega 3 (g) 0.8± 0.9 0.8± 0.7 -0.0± 0.9 0.9± 0.6 0.9± 0.9 -0.0± 1.2 0.9985 0.6499 0.9667 0.9659 
Vitamins 
Thiamin (mg) 1.0± 0.6 1.2± 0.5 -0.2±0.5 1.1± 0.4 1.3± 1.0 -0.2± 1.1 0.2526 0.5375 0.8294 0.8245 
Riboflavin (mg) 1.3± 0.8 1.4± 0.7 0.06± 0.7 1.3± 0.7 1.7± 1.2 -0.4± 1.4 0.2776 0.3999 0.4258 0.3726 
Niacin (mg) 16.4± 9.5 16.7± 6.6 -0.3± 6.4 17.7± 7.4 21.2± 13.4 -3.5± 16.5 0.4424 0.2444 0.5122 0.4837 
Vitamin B12 (mg) 3.2± 3.3 2.8± 2.2 0.5± 2.2 4.4± 6.3 7.1± 16.9 -2.7± 17.9 0.6526 0.2634 0.4973 0.4914 
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Table 4. Cont. 
Parameter Mango Placebo P value P value 
 
Baseline   
(n=17) 
Final         
(n=20) 
Change§ 
Baseline     
(n=18) 
Final         
(n=18) 
Change§ Time 
Treat- 
ment 
Time X 
Treat- 
ment 
change 
from 
baseline 
Vitamin C (mg) 
56.5± 46.8 118.2± 131.2 
-61.6± 
127.1 
81.4± 53.7 
75.1± 
52.7 
6.3± 56.1 0.1707 0.6495 0.0939 0.0615 
Vitamin E (mg) 5.1± 5.7 5.6± 4.9 -0.6±3.8 5.9± 4.9 6.7± 5.8 -0.8± 4.4 0.6016 0.5010 0.9200 0.8534 
Minerals           
Calcium (mg) 
712.2± 414.1 683.5± 333.6 
28.6± 
291.3 
704.6± 
228.9 
759.9± 
382.3 
-55.2± 
433.1 
0.8804 0.6973 0.6353 0.5351 
Iron (mg) 12.7± 6.7 15.2± 7.0 -2.5±7.2 15.1± 5.8 15.0± 9.6 -0.2± 10.4 0.5188 0.5507 0.4932 0.4049 
Magnesium (mg) 
201.7± 138.3 186.5± 118.9 15.2± 52.1 196.6±82.3 
230.8± 
189.9 
-35.7± 
198.5 
0.7875 0.5801 0.4848 0.4122 
Potassium (mg) 1800.8± 
1054.6 
1727.4± 863.7 73.4±744.9 
1894.8± 
726.1 
1951.2± 
937.0 
-56.4± 
1193.7 
0.9705 0.4905 0.7778 0.7211 
Zinc (mg) 7.1± 4.1 7.3± 4.2 -0.2±4.5 7.9± 4.0 7.9± 4.1 -0.0± 5.4 0.8952 0.5281 0.9327 0.9223 
Sodium (mg) 
2790.4±1493.0 2947.5±1218.3 
-157.1± 
846.6 
2894.4± 
1112.1 
2828.44± 
1639.6 
66.0± 
1776.7 
0.8973 0.9831 0.7521 0.6623 
Values are mean ± standard deviation. Significance level set at P value <0.05. monounsaturated fatty acids (MUFAs), polyunsaturated fatty acids 
(PUFAs). § Change means baseline minus final values. 
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Table 5.  Effect of 90 day supplementation with mango or a placebo on physical activity of individuals with moderately elevated blood glucose 
Parameter Mango   Placebo   
P 
value 
  P value 
 
Baseline   
(n=24) 
Final         
(n=25) 
Change§ 
Baseline     
(n=24) 
Final         
(n=23) 
Change§ Time Treatment 
Time 
X 
Treat- 
ment 
change 
from 
baseline 
Physical Activity (minutes) 
Daily Sleep 
429± 69.6 426± 40.4 3.0± 65.2 435± 89.0 418± 47.4 
17.3± 
78.1 
0.4560 0.9500 0.5921 1.0 
Daily Sedentary 
Work  
316± 186.4 351± 169.6 -35.0± 189.2 335± 189.7 369± 163.9 
-34.2± 
204.7 
0.3455 0.6246 0.9935 0.1549 
Daily 
Standing/Walking 
160± 147.6 149± 149.3 11.0± 186.3 142± 153.1 191± 265.6 
-49.1± 
276.5 
0.6139 0.7501 0.4304 0.5942 
Daily Heavy Physical 
Work  
62± 119.7 62± 119.7 0.0± 123.8 73± 134.0 98± 198.0 
-24.9± 
116.8 
0.6821 0.4334 0.6740 0.8284 
Daily Biking/walk to 
work 
22± 311.3 47± 85.3 -26.1± 89.0 30± 63.4 38± 98.7 
-8.2± 
120.3 
0.2724 0.9710 0.5592 0.6178 
Daily Leisure Time 
158± 124.1 146± 61.4 12.3± 118.0 158± 100.3 125± 69.3 
32.8± 
96.5 
0.2324 0.5863 0.5638 0.8864 
Weekly Light 
Activity  
350± 379.2 223±173.7 127.0± 401.3 301± 365.3 394± 555.4 
-93.1± 
571.6 
0.8344 0.4408 0.1691 0.2518 
Weekly Moderate 
activity  
234± 485.5 145± 147.3 88.9± 536.5 184± 244.6 159± 156.2 
25.2± 
267.3 
0.3455 0.7639 0.6004 0.5868 
Weekly Strenuous 
activity  
106± 168.3 111± 151.1 -5.5± 173.1 85± 157.4 135.2± 190.1 
-50.4± 
191.5 
0.4230 0.9685 0.5115 0.3939 
Values are mean ± standard deviation. Significance level set at P value <0.05. § Change means baseline minus final values. 
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Table 6. Effects of 90 days supplementation with mango or a placebo on weight, blood pressure, waist and hip circumference, and body 
composition in individuals with moderately elevated blood glucose 
Parameter Mango  Placebo  P value  P value 
 Baseline 
(n=26) 
Final 
(n=26) 
Change§ 
Baseline  
(n=24) 
Final 
(n=24) 
Change§ Time Treatment 
Time X 
Treatment 
change from 
baseline 
Weight (lbs) 
186.7± 9.1 
193.3± 
39.3 
-6.6± 21.8 189.3± 38.4 
190.9± 
40.0 
-1.6± 6.0 0.5871 0.9753 0.7446 0.1515 
SBP (mm Hg) 128.3± 
15.3 
129.6± 
15.9 
-1.3± 18.2 127.5± 13.0 
130.9± 
12.9 
-3.4± 10.4 0.4217 0.9140 0.7111 0.6276 
DBP (mm Hg) 
80.2± 12.8 
79.5± 
11.6 
0.7± 11.9 81.2± 10.7 79.7± 9.9 1.5± 6.0 0.6290 0.7877 0.8687 0.8537 
BMI (kg/m2) 31.0± 6.6  31.5± 6.9 -0.5± 0.7 30.8± 6.4 31.3± 6.5 -0.5± 4.9 0.7296 0.8693 0.9931 0.2432 
Waist 
circumference 
(in)* 
39.5± 5.6 40.3± 5.8 -0.8± 12.8 40.0± 5.7 39.7± 6.2 0.3± 17.7 0.8604 0.9620 0.6848 0.6972 
Hip 
circumference 
(in)* 
43.5± 5.4 
44.24± 
5.3 
-0.7± 142 44.1± 5.7 44.5± 6.3 -0.4± 17.6 0.6509 0.7515 0.8939 
0.6810 
 
Body Composition 
Area (cm²) 2072.8± 
181.3 
2086.8± 
193.2 
-14.0± 28.5 
2061.5± 
194.5 
2063.1± 
190.6 
-1.6± 32.0 0.8374 0.6470 0.8711 0.3374 
BMC (g) 2447.7± 
361.0 
2587.7± 
766.0 
-140± 614.2 
2397.8± 
334.9 
2407.5± 
325.7 
-9.7± 47.1 0.4450 0.2411 0.5059 0.3460 
BMD (g/cm²) 1.17± 0.1 1.18± 0.1 -0.0± 0.0 1.16± 0.01 1.16± 0.01 -0.00± 0.0 0.9035 0.4621 0.9530 0.4458 
Fat Mass (kg) 30.85± 
12.36 
30.28± 
11.10 
0.58± 1.43 
31.87± 
12.40 
31.95± 
12.38 
-0.76± 1.74 0.9189 0.5841 0.8944 0.7156 
% Fat 35.0± 9.5 34.4± 8.6 0.6± 1.5 36.1± 9.2 36.1± 9.3 0.0± 1.4 0.8560 0.4375 0.8631 0.9768 
Values are mean ± standard deviation. Significance level set at P value <0.05. systolic blood pressure (SBP), diastolic blood pressure (DBP), body 
mass index (BMI), body mass composition (BMC), bone mineral density (BMD).* n= 18 placebo base, 19 placebo final; 21 mango base, 24 
mango final. § Change means baseline minus final values.  
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Table 7. Effects of 90 days supplementation with mango or a placebo on lipids and liver panel in individuals with moderately elevated blood 
glucose 
Parameters Mango  Placebo  P value P value 
 
Baseline 
(n=26) 
Final     
(n=26) 
Change§ 
Baseline 
(n=24) 
Final 
(n=24) 
Change§ Time Treatment 
Time X 
Treat- 
ment 
change 
from 
baseline 
Lipid Panel 
Total Cholesterol (mg/dL) 178.2± 30.7 180.7± 30.8 -2.3± 20.3 181.2± 29.9 178.0± 29.4 3.2± 18.6 0.9281 0.7344 0.7728 0.4914 
Triglycerides (mg/dL) 125.8± 85.2 134.3± 76.8 -9.0± 54.8 127.6± 77.8 117.8± 53.5 9.8± 30.4 0.8929 0.8228 0.6639 0.5093 
LDL Cholesterol (mg/dL) 106.6± 26.5 107.4± 25.6 -0.1± 16.0 105.8± 26.4 103.0± 25.5 2.1± 14.6 0.9881 0.9334 0.8871 0.6221 
HDL Cholesterol (mg/dL) 48.0± 11.3 46.6± 10.3 1.4± 7.3 50.1± 11.4 51.3± 10.0 -1.2± 6.9 0.8094 0.2757 0.7097 0.4211 
VLDL Cholesterol 
(mg/dL) 
25.1± 17.1 26.8± 15.3 -1.8± 11.0 25.5± 15.8 23.5± 10.6 2.0± 6.1 0.8873 0.8286 0.6446 0.4684 
LDL/HDL (mg/dL) 2.4± 1.0 2.4± 0.9 -0.0± 0.4 2.2± 0.9 2.1± 0.7 0.1± 0.4 0.9453 0.4941 0.7863 0.2431 
Hepatic Panel 
Total protein (gm/dL) 7.1± 0.5 7.2± 0.5 -0.1± 0.5 7.1± 0.4 7.1± 0.5 0.0± 0.5 0.8182 0.8105 0.6950 0.6217 
Albumin (gm/dL) 4.2± 0.4 4.2± 0.4 -0.0± 0.3 4.2± 0.3 4.1± 0.4 0.1± 0.4 0.9942 0.9354 0.9293 0.9600 
Globulin (gm/dL) 2.3± 0.4 3.0± 0.4 -0.0± 0.3 2.96± 0.3 2.9± 0.3 0.0± 0.3 0.8405 0.7248 0.5551 0.4231 
AST (U/L) 27.0± 16.1 26.5± 7.5 0.8± 13.5 27.9± 14.5 25.7± 9.7 2.2± 13.0 0.6019 0.9790 0.7509 0.6777 
ALT(U/L) 39.6± 16.6 39.4± 12.1 0.7± 13.0 40.9± 27.9 36.3± 10.0 4.6± 28.5 0.5091 0.7970 0.5476 0.4421 
Alkaline Phosphatase 
(U/L) 
73.5± 17.2 76.7± 15.5 -2.1± 12.5 76.4± 21.8 78.9± 21.2 -2.5± 11.7 0.4622 0.5046 0.9293 0.9260 
Bilirubin (gm/dL) 0.2± 0.2 0.3± 0.1 -0.1± 0.2 0.2± 0.1 0.3± 0.1 -0.1± 0.1 0.0017 0.8108 0.1588 0.1222 
Values are mean ± standard deviation. Significance level set at P value <0.05. low-density lipoprotein (LDL), high-density lipoprotein 
(HDL), very-low-density lipoprotein (VLDL), aspartate aminotransferase (AST), alanine transaminase (ALT). § Change means baseline 
minus final values.  
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Table 8. Effects of 90 days supplementation with mango or a placebo on glucose parameters in individuals with moderately elevated blood 
glucose 
Parameters Mango  Placebo  P value P value 
 
Baseline 
(n=26) 
Final   
(n=26) 
Change§  
Baseline 
(n=24) 
Final   
(n=24) 
Change§  Time Treatment 
Time X 
Treat- 
ment 
change 
from 
baseline 
Glucose (mg/dL) 97.5± 9.4 95.5± 9.0 2.0± 7.5 97.8± 10.9 97.9± 10.7 0.1± 9.1 0.5953 0.5117 0.6381 0.4346 
HbA1C % 5.4± 0.3 5.4± 0.3 -0.0± 0.3 5.4± 0.3 5.4± 0.3 -0.3± 1.2 0.3894 0.9487 0.9008 0.3076 
Insulin (mg/mL) 6.45± 3.3 6.6± 3.4 -0.3± 2.0 6.2± 3.7 6.2± 4.1 -0.1± 1.8 0.9072 0.6977 0.9988 0.7707 
HOMA-
IR(mg/mL) 
1.6± 0.9 1.6± 0.9 -0.0± 0.5 1.5± 1.1 1.6± 1.2 -0.0± 0.5 0.9646 0.8823 0.9143 0.9877 
GTT2 hr (mg/dL)*  107.6± 41.8   105.1± 42.1   0.8427   
Values are mean ± standard deviation. Significance level set at P value <0.05. glycated hemoglobin (HbA1C %), homeostatic model assessment- 
insulin resistance (HOMA-IR), 2 hour glucose tolerance test (GTT2 hr).*n= 26 and 22 individuals for the mango and placebo treatments, 
respectively. § Change means baseline minus final values. 
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Table 9. Effect of 90 day supplementation with mango or a placebo on plasma diabetes parameters in individuals with moderately elevated blood 
glucose 
Parameter Mango  Placebo  P value P value 
 
Baseline   
(n=21) 
Final          
(n=21) 
Change§ 
Baseline     
(n=20) 
Final         
(n=20) 
Change§ Time 
Treat- 
ment 
Time X  
Treat- 
ment 
change 
from 
baseline 
C-Peptide  
(pg/mL) 
1564.3± 651.7 1520.6± 667.2 
43.7+ 
184.0 
1468.4± 636.8 1564.89± 710.1 
-96.5+ 
288.3 
0.8583 0.8616 0.6355 0.0697 
Ghrelin 
(pg/mL) 
1272.6±520.7 1284.8±551.3 
-12.2± 
251.6 
1628.6±736.2 1666.41±790.3 
-37.8± 
3338.4 
0.8637 0.0130 0.9299 0.7841 
Leptin 
(mg/dL)* 
16.0± 14.2 19.7± 18.3 -3.7± 8.8 18.1±  16.7 20.0± 22.6 
-1.9± 
12.4 
0.9544 0.7404 0.9521 0.7412 
Adiponectin 
(µg/mL)** 
9.3± 6.0 9.1± 5.3 0.2± 3.0 8.8± 6.5 9.0± 7.1 
-0.1± 
2.3 
0.9906 0.8408 0.8829 0.4531 
GIP (pg/mL) 
565.2±314.5 551.8±291.1 
13.4± 
343.0 
490.1±171.8 632.7±384.7 
-142.7± 
298.7 
0.3335 0.2434 0.9653 0.1290 
GLP-1 
(pg/mL) 
324.5±53.8 321.1±51.7 
3.4± 41.9 
302.1±37.9 306.1±51.9 
-4.1± 
45.4 
0.9746 0.0901 0.7333 0.5873 
Glucagon 
(pg/mL) 
316.2±106.1 308.7±89.5 
7.5± 40.1 
331.9±108.8 344.7±122.7 
-12.9 
63.6 
0.9107 0.2777 0.6689 0.2255 
PAI-1 
(pg/mL) 
6350.8±2611.3 6498.5±2614.9 
-147.8± 
2230.0 
6265.0±1959.7 6211.4±2358.9 
53.6± 
2410.8 
0.9297 0.7268 0.8504 0.7827 
Resistin 
(pg/mL) 
3965.0±1169.1 4097.1±1234.3 
-132.2± 
571.4 
4179.6±1297.1 4516.5±1519.3 
-337.0± 
656.7 
0.4198 0.2764 0.7243 0.2927 
Visfatin 
(pg/mL) 
1148.0±720.6 959.8±619.2 
188.3± 
613.5 
1145.2±636.4 889.5±631.6 
255.7± 
1046.0 
0.1283 0.8010 0.8161 0.8014 
Values are mean ± standard deviation. Significance level set at P value <0.05. connecting peptide (C-Peptide), gastric inhibitory peptide (GIP), 
glucagon-like peptide 1 (GLP-1), plasminogen activator inhibitor-1 (PAI-1). § Change means baseline minus final values. *n=22 and 21 
individuals for the mango and placebo treatments, respectively. **n=24 and 22 individuals for the mango and placebo treatments, respectively. 
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Table 10.  Effect of 90 day supplementation with mango or a placebo on plasma cytokines in individuals with moderately elevated blood glucose 
Parameter  Mango  Placebo  P value  P value 
 
Baseline 
(n=21) 
Final   
(n=21) 
Change§ 
Baseline 
(n=20) 
Final       
(n=20) 
Change§ Time Treatment 
Time X 
Treatment 
Change 
from 
baseline 
IL-1β 
(pg/mL) 
2.77± 3.6 2.4± 2.8 0.4± 2.0 2.78± 3.8 3.11 ± 3.6 -0.3± 1.8 0.9851 0.6343 0.6496 0.2422 
IL-1ra 
(pg/mL) 
89.31±101 85.75±78.3 3.6± 55.7 109.9± 109 113.59±121.2 -3.7± 52.7 0.9977 0.2917 0.8739 0.6705 
IL-2 
(pg/mL) 
4.28±7.4 3.21±3.9 1.1± 5.9 5.65± 11.9 5.19±9.2 0.5± 6.1 0.6871 0.3792 0.8712 0.7448 
IL-4 
(pg/mL) 
1.66±2.2 1.86±1.6 -0.2± 1.7 2.36±11.9 2.18±2.2 0.2± 1.8 0.9799 0.3111 0.7089 0.4945 
IL-5 
(pg/mL) 
13.76±12.7 12.17±10.9 1.6± 9.2 13.05±11.1 13.89±12.5 -0.8± 8.7 0.8868 0.8468 0.6424 0.3901 
IL-6 
(pg/mL) 
4±5.6 3.21±4.1 0.8± 3.6 4.97±6.5 5.16±7.2 -0.2± 3.4 0.8006 0.2753 0.6981 0.3522 
IL-7 
(pg/mL) 
13.32±18.6 14.37±14.6 -1.0± 11.2 21.38±33.7 18.15±19.6 3.2± 16.8 0.8278 0.2407 0.6705 0.3415 
IL-8 
(pg/mL) 
11.6±11 11.05±7.8 0.5± 7.2 15.75±15.9 13.92±12.8 1.8± 8.3 0.6603 0.1961 0.8127 0.6004 
IL-9 
(pg/mL) 
24.53±19.2 23.82±14.1 0.7± 12.9 35.25±31.8 31.32±26.5 3.9± 10.7 0.6593 0.0860 0.7596 0.3895 
IL-10 
(pg/mL) 
12.86±14.4 11.03±9.5 1.8± 9.0 19.99±26.8 16.94±17.5 3.1± 12.1 0.5423 0.1060 0.8790 0.7156 
IL-12p70 
(pg/mL) 
31.48±44 20.33±20.2 11.2± 30.9 51.66±103.7 38.98±59.6 12.7± 47.7 0.4011 0.1730 0.9570 0.9032 
IL-13 
(pg/mL) 
10.94±7.9 10.20±8.3 0.7± 5.2 21.36±28.1 16.45±15.7 4.9± 14.7 0.4511 0.0284 0.5777 0.2277 
Eotaxin 
(pg/mL) 
102.87±70.
2 
101.67±56 1.2± 38.7 102.07±53.4 111.73±53.5 -9.7± 34.2 0.7454 0.7227 0.6772 0.2775 
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Table 10. Cont. 
Parameter Mango Placebo P value P value 
 
Baseline 
(n=21) 
Final    
(n=21) 
Change§ 
Baseline 
(n=20) 
Final       
(n=20) 
Change§ Time Treatment 
Time X 
Treat- 
ment 
Change 
from 
baseline 
Basic FGF 
(pg/mL) 
48.11±47.8 39.95±33.5 8.2± 28.2 59.12±70 56.65±59.7 2.5± 27.6 0.6583 0.2507 0.8124 0.5163 
GCSF 
(pg/mL) 
71.68±54.3 68.7±38.9 3.0± 38.8 107.42±125.8 95±67.9 12.1± 68.4 0.6629 0.0778 0.7918 0.5986 
GMCSF 
(pg/mL) 
33.48±55.5 32.19±54 1.3± 12.4 27.81±51.4 21.47±36.6 6.3± 22.0 0.7310 0.4607 0.8198 0.3673 
IFNγ 
(pg/mL) 
102.7±114.
3 
118.11±95.1 -15.4± 87.1 135.47±119.6 139.82±111.6 -4.4± 85.9 0.6864 0.2675 0.8214 0.6851 
IP-10 
(pg/mL) 
1165.82±65
5.6 
1055.24±450.
8 
110.6± 462.0 
1382.9±1076.
4 
1313.53±108
9.5 
69.4± 
362.3 
0.6458 0.2129 0.9136 0.7531 
MCP-1 
(pg/mL) 
3.91±8.8 4±6.8 -0.1± 4.9 5.72±16.4 6.5±14 -0.8± 9.2 0.8701 0.4207 0.8977 0.7645 
MIP-1α 
(pg/mL) 
5.95±5.3 4.56±3.5 1.4± 3.1 7.55±9.7 6.66±7.2 0.9± 4.3 0.4499 0.2214 0.8679 0.6679 
MIP-1β 
(pg/mL) 
75.43±53.7 76.16±47.8 -0.7± 37.3 82.78±60.7 77.89±55.3 4.9± 21.4 0.8632 0.7071 0.8160 0.5600 
PDGFBB 
(pg/mL) 
138.19±184
.73 
159.12±184.2 -21.0± 212.0 137.42±115 184.26±202.1 
-46.8± 
191.8 
0.3834 0.7535 0.7384 0.6842 
RANTES 
(pg/mL) 
4315.93±33
48.6 
5230.02±298
7.4 
-914.1+ 
2865.2 
5782.3±3246.
5 
4259.01±258
2.8 
1523+ 
2406.8 
0.6534 0.7150 0.0752 0.6842 
TNF-α 
(pg/mL) 
18.94±21.9 22.61±22.4 -3.7± 24.8 42.94±57.9 35.59±46.8 7.4± 19.7 0.8355 0.0399 0.5349 0.1240 
VEGF 
(pg/mL) 
14.06±20.5 10.32±13.7 3.7± 11.0 26.6±52.5 19.75±30.7 6.8± 25.0 0.4634 0.1301 0.8293 0.6066 
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Table 10. Cont. 
Parameter Mango Placebo P value P value 
 
Baseline 
(n=21) 
Final        
(n=21) 
Change§ 
Baseline 
(n=20) 
Final          
(n=20) 
Change§ Time Treatment 
Time X 
Treatment 
Change 
from 
baseline 
TBARS 
(µM)* 
28.9± 25.0 38.2± 75.6 -9.4± 83.2 40.1± 51.5 27.3± 16.2 12.7± 45.3 0.8895 0.9916 0.3665 0.3617 
Anti- 
oxidants 
(mM) 
3.0± 2.7 2.7± 2.1 0.3± 1.5 3.7± 7.6 4.2± 2.7 -0.5± 1.9 0.8446 0.0371 0.4049 0.1045 
Values are mean ± standard deviation. Significance level set at P value <0.05.  interleukin-1 beta (IL-1β), interleukin-1 receptor antagonist (IL-
1ra), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6(IL-6), interleukin- 7(IL-7), interleukin-8 (IL-8), interleukin- 9 
(IL-9), interleukin-10 (IL-10), interleukin- 12p70(IL-12p70), interleukin-13 (IL-13), fibroblast growth factor (FGF), granulocyte colony-
stimulating factor (GCSF), granulocyte macrophage colony-stimulating factor (GMCSF), interferon gamma (IFNγ), interferon gamma-induced 
protein -10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1α), macrophage 
inflammatory protein-1 beta(MIP-1β), platelet-derived growth factor-beta (PDGF-BB), chemokine ligand 5(RANTES), tumor necrosis factor-
alpha (TNF-α), vascular endothelial growth factor (VEGF) thiobarbituric acid reactive substances (TBARS) *n=15 baseline and 15 final and 16 
baseline and 16 final individuals for the mango and placebo treatments, respectively. § Change means baseline minus final values.  
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CHAPTER V 
 
 
DISCUSSION AND CONCLUSION 
 
 
This study investigated the effects of daily supplementation of freeze-dried mango (10 
g/d) for 12 weeks on diabetes markers, anthropometrics, body composition, lipid parameters, and 
inflammatory markers in individuals with moderately elevated blood glucose. This study is a 
follow-up of our animal study that demonstrated that mango was able to modulate blood glucose 
in mice fed a high fat diet, a model of diet-induced obesity 19. We have also conducted a clinical 
study that investigated the effects of daily supplementation of the same dose of freeze-dried 
mango on clinical parameters of obese individuals and found that mango supplementation 
improved blood glucose in these individuals after twelve weeks of supplementation 61. The 
findings of the current study, however, showed that mango supplementation has no effect on 
glucose parameters in individuals with moderately elevated blood glucose. Because of the very 
sweet taste of the mango fruit, the popular belief is that consumption of this fruit is not a good 
choice for individuals at risk or with diabetes. However, our findings demonstrate that freeze-
dried mango neither increases nor decreases blood glucose in these individuals. 
We accept our null hypothesis that mango supplementation has no effect on fasting blood 
glucose in individuals with elevated blood glucose. Additionally, there was no significant  
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difference found in glycated hemoglobin A1C (HbA1C%), a measure of average plasma glucose 
concentration over a three month period. The National Institute of Health categorized HbA1C% 
values less than 5.7% to be normal while values between 5.7% and 6.4% are a diagnosis for pre-
diabetes 63. The average HbA1C in our study was 5.4% for both groups, which falls in the 
category for normal healthy individuals. Mango supplementation may not have had an effect on 
blood glucose and HbA1C% in our study participants because it was not high enough to correct. 
Nonetheless, mango supplementation did not cause negative effects on blood glucose nor 
HbA1C. Our screening for study participants only used a finger stick fasting blood glucose 
assessment using a home testing glucometer and not based on HbA1C. If there are no budgetary 
or other experimental constraints, future studies should use HbA1C as the screening tool to 
identify study participants. 
No changes in fasting blood glucose, insulin, or HOMA-IR were observed after 12 weeks 
of mango supplementation. We also did not see changes in glucose tolerance testing measures in 
either treatment group. Our findings are not in agreement with the findings of Evans et al. where 
they saw a significant difference in fasting blood glucose with mango supplementation in obese 
individuals 61. Differences in these findings could be due to different effects in obese individuals 
or adherence to the study protocol of consuming the supplement daily. Perhaps mango has an 
effect on glucose uptake in the adipose tissue such that a glucose lowering effect was observed by 
Evans and colleagues 61. The effect of mango supplementation on adipose tissue has also been 
demonstrated by Lucas and colleagues 19. They found that 1% mango supplementation for two 
months was able to significantly decrease body fat in rats fed a high fat diet 19. However, when a 
similar dose of mango was consumed by obese individuals there were no significant differences 
found in fat mass after 12 weeks of supplementation but a reduction in fasting blood glucose was 
observed 61. To examine whether the effects of mango on blood glucose is dependent on 
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adiposity, we separated and analyzed the data for the obese (BMI > 30 kg/m2) participants in the 
current study. Mango was still not able to lower blood glucose in obese individuals.  
Very few studies have examined the glucose-lowering effect of the mango fruit. Most of 
the studies investigating the glucose-lowering effect of mango have used an extract of the 
different parts of the mango plant. Aderibigbe and colleagues found that aqueous extract of 
mango leaves modulated fasting blood glucose level and glucose tolerance test in rats with 
glucose-induced hyperglycemia 55. The aqueous mango leaf extract was given orally to one group 
60 minutes prior to the glucose challenge and in another group the extract was given together 
with the glucose challenge. Both groups had lower blood glucose levels at 30 and 60 minutes; 
however, rats given the extract prior to the glucose challenge maintained blood glucose level up 
to 120 minutes 55. These findings could indicate that a higher concentration of the bioactive 
compound in mango (i.e. extract) may be needed for glucose lowering effects. This could also 
indicate that the timing of mango supplementation may play a role in its glucose-lowering 
capabilities. Since the mango extract given 60 minutes prior to the glucose challenge resulted to a 
lower blood glucose level concentration for a longer period, perhaps mango needs to be 
consumed before a meal to induce a more profound glucose lowering properties. It has been 
suggested that the fiber content of the mango slows down gut transit time and therefore slows 
down the absorption of glucose 58. It is possible that we might need to have our study participants 
consume the freeze-dried mango supplements at strategic times before meals and not just once a 
day as our protocol required. However, this is a speculation and needs to be further investigated. 
The component of the mango fruit responsible for lowering blood glucose is not clear. 
Previous studies have attributed the glucose lowering effect of mango to be due to its fiber 
content 58. A meta-analysis found that an increase in fiber intake by approximately 18 g/d can 
reduce fasting blood glucose and HbA1C 64. The American Dietetic Association recommends 30-
50 g/d dietary fiber for individuals with T2D 64. The mean total fiber intake of our study 
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participants for both groups (16-18 g fiber/d without the mango supplementation which provided 
1.29 g/d) is much lower than the recommended fiber intake and lower in studies that found a 
correlation between fiber intake and blood glucose. Perhaps, a larger dose of mango would be 
needed to provide the amount of fiber these studies found to be beneficial.  
The glucose-lowering properties of mango have been compared to other fruits. 
Roongpisuthipong and colleagues measured post-prandial glucose and insulin response in 
diabetic female participants. They found that when compared to banana, durian, rambutan, and 
pineapple, mango had a significantly lower post-prandial plasma glucose and insulin response 59. 
Edo and colleagues found that mango had one of the lowest mean postprandial glucose levels and 
the lowest peak postprandial glucose level when compared to banana, orange, pineapple, and 
pawpaw 58. This shows that even though we did not see a glucose lowering effect with chronic 
mango supplementation, it might have an effect on post-prandial response.  
In this study, we did not observe differences in anthropometrics parameters among the 
treatment groups. However, we did not expect to see differences in anthropometrics parameters 
since the subjects were asked to maintain their current diet and physical activity patterns. The 
study participants had normal blood pressure throughout the study and no changes in waist or hip 
circumference were observed. Both groups had an average BMI of 31 kg/m2, which is classified 
as obese. Obesity is a risk factor for T2D and mango supplementation did not have any effects on 
BMI. Additionally, no differences were found in body composition between the treatment group 
and the control. This is consistent with the findings of Evans et al., which did not see significant 
changes in body weight and composition after mango supplementation 61.  
We saw minimal significant changes in the lipid profile of subjects on either treatment.  
Saleh and colleagues found that 20 mg/kg/d mangiferin supplementation in high fat fed 
streptozotocin (STZ)-induced diabetic rats reduced circulating and liver triglycerides and 
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cholesterol 57. Our findings were also not consistent with the findings of Robles-Sanchez and 
colleagues which found both whole mango and fresh cut mango to significantly lower fasting 
plasma triglycerides and VLDL after 30 days of mango supplementation in subjects considered to 
be in good health 60. Each subject was asked to consume 200 g mango per day. Our study 
participants consumed 10 g freeze-dried mango per day which is equivalent to about 50-100 g 
fresh mango or half a fruit. Perhaps a higher dose of freeze-dried mango or fresh mango is needed 
to affect blood lipids. Another study by Muruganandan and colleagues also showed that mango 
supplementation improved lipid profiles in rats.  Mango extract  (10 and 20 mg/kg i.p.) was as 
effective as insulin (6 U/kg i.p.) at lowering blood glucose, triglycerides, total cholesterol, LDL 
cholesterol, and increasing HDL cholesterol after just 28 days of supplementation in STZ-induced 
diabetic rats 14. These two studies show that mango is capable of improving blood lipids in 
diabetic rats and also in humans when the mango supplement is given in large enough amounts. 
One finding in this study was a significant increase in bilirubin in both groups after 90 
days of supplementation. An animal study done by Fu and colleagues looked at two strains of rat 
(Winstar and Gunn rats) and bilirubin levels. The Gunn rat is used as a model for jaundice 
because they lack the enzyme bilirubin glucuronide preventing bilirubin to be combined with bile 
and thus accumulating in the blood. They found that in the Gunn rats, the excess bilirubin was 
able to stabilize plasma insulin levels of the STZ-induced diabetic rats but not in Winstar rats 65. 
This may shows that bilirubin has the ability to preserve insulin secretion from the pancreatic 
islets in hyperbilirubinemic animals. They found that bilirubin concentrations as low as 1.7 
gm/dL prevented apoptosis in rat insulinoma cells 65. The National Health and Nutrition 
Examination Survey (NHANES) also reported that higher bilirubin levels may protect against 
T2D 66, 67. Our study participants in both groups experienced an average increase of 0.1 gm/dL 
bilirubin after 90 days of supplementation. While still within the normal range, the mean bilirubin 
values are still much lower than the values seen in previous studies 65, 67. A longer period of 
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supplementation may be required to induce a greater increase in bilirubin in individuals with 
elevated blood glucose.  
 Of the diabetes parameters measured, C-peptide, GIP, and GLP-1, all markers of insulin 
production, did not change before and after the twelve-week supplementation with mango or 
placebo. Visfatin, an enzyme that promotes β-cell maturation and is therefore associated with 
insulin production did not change throughout the study. This supports our findings of mango not 
having an effect on blood glucose since insulin allows for the entry of glucose into the cell. Evans 
and colleagues saw a mild increase in insulin of male obese subjects after twelve weeks of mango 
supplementation but not in obese female subjects 61. A study conducted by Sellamuthu and 
colleagues found that mangiferin protected pancreatic β-cells from oxidative stress and therefore 
increased insulin secretion and decreased blood glucose in STZ-induced diabetic rats 68. The 
discrepancies in the findings of Sellamuthu and colleagues and that of Evans et al. and our 
present study could be due to the dose of mango used and possibly the amount of phenolic 
compound mangiferin 61, 68.  
Ghrelin, leptin and adiponectin, all involved in metabolic processes, were not changed 
with mango supplementation. Saleh and colleagues found that 20 mg/kg/d mangiferin 
supplementation increased adiponectin in STZ-induced diabetic rats after 28 days of 
supplementation 57. Our findings show that mango does not have an effect on these parameters in 
individuals with moderately elevated blood glucose. Glucagon, which raises the concentration of 
glucose in the blood, was also not affected by freeze-dried mango supplementation. PAI-1 and 
resistin, both correlated with increased adiposity did not differ from baseline to final. There was 
also no difference in body composition or percent body fat so we would not expect for PAI-1 or 
resistin levels to change. Mango did not differ from the control group in any of these parameters 
suggesting that mango did not increase the risk of T2D.   
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 Chronically elevated inflammatory cytokines are typically present in disease states like 
T2D 69. The increase in inflammatory cytokines can cause damage by producing an excess 
amount of reactive oxygen species (ROS). A surplus of ROS can result in oxidative stress causing 
damage to proteins, lipids, and DNA as well as disrupting cellular signaling, contributing to the 
damage and dysfunction 35. Of the twenty-five cytokines measured, we did not see any significant 
changes. A previous human study found that the concentrations of the inflammatory cytokines 
TNF-α and MCP-1, increased in the presence of diabetes 69. Moreover, Saleh and colleagues 
found that mangiferin (20 mg/kg/d) supplementation for 28 days decreased serum TNF-α in high-
fat diet fed STZ-induced diabetic rats 57. Mangiferin was also able to cause a significant reduction 
in airway inflammation and a positive immunomodulatory effect (increased IL-2, IL-10, IL-12, 
IFN-γ and decreased IL-3, IL-4, IL-5, IL-9, IL-13, IL-17, RANTES, and TNF) in a mouse model 
of chronic respiratory disease 70. Perhaps we did not see any differences in some of these 
cytokines because they are not directly associated with diabetes.  
 Thiobarbituric acid reactive substances (TBARS), which assess lipid peroxidation was 
not affected by mango supplementation. Rodriguez and colleagues incubated red blood cells with 
H2O2 and mangiferin and measured lipid peroxidation by TBARS. Mangiferin (1μg/mL) 
decreased lipid peroxidation and a higher dose (100 μg/mL) decreased the damage to that of the 
cells not treated with H2O2 71. Sellamuthu and colleagues found that in STZ- induced diabetic 
rats, mangiferin (40 mg/kg/d) supplementation decreased TBARS after 30 days of treatment 68. 
The discrepancy with the in vitro and animal studies and our findings of no effects on TBARS 
concentrations may be due to low bioavailable concentrations of mangiferin from our freeze-dried 
mango. 
We observed significantly lower plasma total antioxidants in the mango group compared 
to the control group. These results were very surprising considering ¾ cup of mango contains 
27.7 mg of vitamin C and 4.2 mg of vitamin E, while the placebo does not contain any 
51 
 
antioxidants. The food recalls collected three times during each arm of the study showed no 
difference in the dietary anti-oxidant between the mango and placebo groups. It is uncertain why 
the control group has higher plasma antioxidant but this may help explain the lack of significance 
in most of the parameters measured. A meta-analysis of 14 studies showed that antioxidant 
supplementation does not affect plasma glucose and insulin levels, yet antioxidant 
supplementation significantly reduced HbA1C level 72. Curiously, Savu and colleagues found that 
total antioxidant activity as well as residual antioxidant activity was significantly higher in 
patients with uncomplicated T2D compared to a healthy control 73. It is known that antioxidants 
improve oxidative stress such as those generated by complications of diabetes but some 
contradicting results are also available. 
 There were no significant differences for either group considering food intake or physical 
activity, except that vitamin C intake tended to increase for the mango group from baseline to 
final. The study participants were asked to not make any changes to their dietary and physical 
activity habits during their participation in the study. The tendency of vitamin C to increase in the 
mango group during the study could be due to the study participants consuming the supplement 
by adding it to a cup of orange juice.  
 This study is not without limitations. For one, we cannot be certain whether the study 
participants stored the supplements properly or consumed the supplements daily. Although they 
were given calendars to record their intake of the supplements, over-reporting can still occur. It 
would have been better if we can observe the participants actually consuming the supplements or 
if we can assess some markers associated with mango consumption such as mangiferin levels. A 
small sample size may allow for the presence of outliers to have a greater influence on the results. 
Using a twelve week intervention period may not have been enough time for the freeze-dried 
mango supplement to cause significant changes in individuals with moderately elevated blood 
glucose. Another limitation of this study is that a home glucometer testing kit was used for the 
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screening of the study participants. The home glucometer measures whole blood glucose which 
makes the screening blood glucose on the high side. When plasma was used, the average fasting 
blood glucose as well as HbA1C is within normal range. This limited our study because our 
subjects did not have a blood glucose value significantly high enough to correct. Another 
limitation is the dose of mango used in the study. The study subjects were asked to consume 10 
g/d mango, which is much lower than some previous studies 14, 60, 68. Though 10 g/d is a practical 
amount of supplement to consume, it may not be enough to induce positive effects. 
 Although we did not see a reduction in blood glucose parameters with twelve weeks of 
freeze-dried mango supplementation, our findings indicate that chronic consumption of mango by 
individuals with moderately elevated blood glucose does not cause negative changes in blood 
glucose, body weight, lipid parameters, and inflammatory markers associated with T2D. Our 
findings also indicate that mango may have protective effects by increasing bilirubin levels. 
Additional clinical trials with longer duration of mango supplementation and larger sample sizes 
still need to be conducted. 
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